220707-94-8

Basic information

• Product Name: 3-(3,4-dichlorophenyl)prop-2-yn-1-ol
• Synonyms: 3-(3,4-dichlorophenyl)prop-2-yn-1-ol
• CAS NO: 220707-94-8
• Molecular Formula: C₉H₆Cl₂O
• Molecular Weight: 201.05
• Mol File: 220707-94-8.mol

Chemical Properties

• Boiling Point: 314.812 °C at 760 mmHg
• Flash Point: 127.406 °C
• Appearance: /
• Density: 1.41
• CAS DataBase Reference: 3-(3,4-dichlorophenyl)prop-2-yn-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,4-dichlorophenyl)prop-2-yn-1-ol(220707-94-8)
• EPA Substance Registry System: 3-(3,4-dichlorophenyl)prop-2-yn-1-ol(220707-94-8)

Safety Data

• Hazardous Substances Data: 220707-94-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
3-(3,4-dichlorophenyl)prop-2-yn-1-ol is utilized as a crucial intermediate in the synthesis of pharmaceuticals and agrochemicals, playing a pivotal role in the development of new drugs and agricultural products. Its chemical structure allows for the creation of a wide range of compounds with potential therapeutic and pesticidal properties.
Used in Antimicrobial and Anti-Fungal Applications:
Leveraging its inherent antimicrobial and antifungal properties, 3-(3,4-dichlorophenyl)prop-2-yn-1-ol is employed in applications that require the inhibition of microbial growth. This makes it suitable for use in various sanitizing and preservation processes, particularly in the context of medical and environmental health.
Used in Specialty Chemicals and Industrial Materials Production:
3-(3,4-dichlorophenyl)prop-2-yn-1-ol also finds use in the production of specialty chemicals and industrial materials, where its unique properties can be harnessed to enhance the performance or characteristics of the end products. Its versatility in chemical reactions and synthesis processes makes it an important component in the manufacturing of various materials.
It is important to handle 3-(3,4-dichlorophenyl)prop-2-yn-1-ol with care due to its potential hazards, which include irritant and harmful effects if ingested or inhaled. Proper safety measures should be taken to mitigate any risks associated with its use in various applications.

Upstream product

• 20555-91-3 3,4-dichloroiodobenzene 
• 107-19-7 propargyl alcohol 

Downstream Products

• 1010684-85-1 3-(3,4-dichlorophenyl)prop-2-yn-1-al 
• 1628200-44-1 1,2-dichloro-4-(1,1,1-trifluorobuta-2,3-dien-2-yl)benzene 
• 1628200-55-4 3-(3,4-dichlorophenyl)prop-2-yn-1-yl 2-bromo-2,2-difluoroacetate 
• 39960-05-9 3-(3 ,4-dichlorophenyl)propan-1-ol 

Relevant articles and documents

Nickel(II)-Catalyzed Asymmetric Propargyl [2,3] Wittig Rearrangement of Oxindole Derivatives: A Chiral Amplification Effect

A highly enantioselective [2,3] Wittig rearrangement of oxindole derivatives was realized by using a chiral N,N′-dioxide/NiII complex as the catalyst under mild reaction conditions. A strong chiral amplification effect was observed, and allowed access to chiral 3-hydroxy 3-substituted oxindoles bearing allenyl groups in high yields and enantioselectivities (up to 92 % ee) by using a ligand with only 15 % ee. A reasonable explanation was given based on the experimental investigations and X-ray crystal structures of enantiomerically pure and racemic catalysts. Moreover, the first catalytic kinetic resolution of racemic oxindole derivatives by a [2,3] Wittig rearrangement was realized with high efficiency and stereoselectivity.

Ligand-Controlled Regioselective Copper-Catalyzed Trifluoromethylation To Generate (Trifluoromethyl)allenes

(Chemical Equation Presented) "Cu-CF3" species have been used historically for a broad spectrum of nucleophilic trifluoromethylation reactions. Although recent advancements have employed ligands to stabilize and harness the reactivity of this key organometallic intermediate, the ability of a ligand to differentiate a regiochemical outcome of a Cu-CF3-mediated or -catalyzed reaction has not been previously reported. Herein, we report the first example of a Cu-catalyzed trifluoromethylation reaction in which a ligand controls the regiochemical outcome. More specifically, we demonstrate the ability of bipyridyl-derived ligands to control the regioselectivity of the Cu-catalyzed nucleophilic trifluoromethylation reactions of propargyl electrophiles to generate (trifluoromethyl)allenes. This method provides a variety of di-, tri-, and tetrasubstituted (trifluoromethyl)allenes, which can be further modified to generate complex fluorinated substructures.

AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

CHEMICAL COMPOUNDS

The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof: formula (I), wherein G is selected from a group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, or a

NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE

The invention provides novel arylbicyclo[3.1.OJhexylamines, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system

AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE

The present invention relates to novel compounds of formula (I)′, pharmaceutically acceptable salts, prodrugs or solvates thereof: wherein R1 is hydrogen or C1-4alkyl; R2 is a group A, K or W wherein A is (II) K is an α or β naphthyl group, optionally substituted by 1 or 2 groups R18, each of them being the same or different; and W is (III) and wherein G is a 5,6-membered monocyclic heteroaryl, or a 8- to 11-membered heteroaryl bicyclic group; such G may be substituted by (R15)p, which can be the same or different; p is an integer from 0 to 5; R3 is selected in the group consisting of: hydrogen, fluorine, and C1-4alkyl; or corresponds to a group X or X1; R4 is selected in the group consisting of: hydrogen, fluorine, and C1-4alkyl; or corresponds to a group X or X1; R5 is hydrogen or C1-4alkyl; R7 is hydrogen or C1-4alkyl; or is a group X, X1, X2 or X3; wherein X is (IV) X1 is (V) X2 is (VI) and X3 is (VII) R6 is hydrogen or C1-4alkyl; or is a group X or X1; R9 is C1-4alkyl; R10 is selected from a group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R8 is a 5-6 membered heterocycle group, which may be substituted by one or two substituents selected from a group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl; R11 is selected from a group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4aIkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R12 is selected from a group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4aIkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R13 is selected from a group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R14 is selected from a group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4aIkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R15 is selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R16 is hydrogen, C1-4alkyl, C3-6cycloalkyl or C3-6cycloalkylC1-3alkyl; R17 is hydrogen or C1-4alkyl; R18 is selected from a group consisting of: halog